SCHEMBL9913554

SCHEMBL9913554

N#CCc1ccccc1Cc1ccc2[nH]ccc2c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IMPDH2 P12268 1/20 0.44
IMPDH1 P20839 1/20 0.44
NPC1 O15118 1/20 0.41
KDM1A O60341 1/20 0.40
MAOA P21397 1/20 0.40
MAOB P27338 1/20 0.40
CYP17A1 P05093 1/20 0.40
CYP11B1 P15538 1/20 0.40
CYP11B2 P19099 1/20 0.40
PIK3CA P42336 1/20 0.39
PIK3CG P48736 1/20 0.39
SLC6A2 P23975 3/20 0.39
SLC6A4 P31645 3/20 0.39
SLC6A3 Q01959 3/20 0.39
ALOX5AP P20292 1/20 0.39
PRKCQ Q04759 1/20 0.37
AHR P35869 4/20 0.37
TRPA1 O75762 1/20 0.37
CA1 P00915 1/20 0.37
CA2 P00918 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30087878 0.81 IMPDH2 (0.55) IMPDH2IMPDH1NPC1KDM1AMAOA
SCHEMBL6584733 0.81 IMPDH2 (0.55) IMPDH2IMPDH1NPC1KDM1AMAOA
SCHEMBL1570686 0.81 SLC6A2 (0.55) IMPDH2IMPDH1NPC1KDM1AMAOA
SCHEMBL9913549 0.81 NPC1 (0.44) IMPDH2IMPDH1NPC1KDM1AMAOA
SCHEMBL9913530 0.81 NPC1 (0.44) NPC1KDM1AMAOAMAOBCYP17A1
SCHEMBL1571266 0.81 NPC1 (0.44) NPC1KDM1AMAOAMAOBCYP17A1
SCHEMBL9888410 0.78 NPC1 (0.41) NPC1KDM1AMAOAMAOBCYP17A1
SCHEMBL13539226 0.78 NPC1 (0.45) NPC1KDM1AMAOAMAOBCYP17A1
SCHEMBL9888407 0.78 NPC1 (0.41) NPC1KDM1AMAOAMAOBCYP17A1
SCHEMBL1570778 0.78 GFER (0.49) NPC1KDM1AMAOAMAOBCYP17A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8198274-B2 Substituted indolyl and indazolyl derivatives and uses thereof ROCHE PALO ALTO LLC (US) 2012-06-12 US disclosed
US-8198274-B2 Substituted indolyl and indazolyl derivatives and uses thereof ROCHE PALO ALTO LLC (US) 2012-06-12 US disclosed
US-20100016312-A1 Substituted indolyl and indazolyl derivatives and uses thereof ROCHE PALO ALTO LLC 2010-01-21 US disclosed
WO-2010006945-A1 SUBSTITUTED INDOLYL AND INDAZOLYL DERIVATIVES AND USES THEREOF F. HOFFMANN-LA ROCHE AG (CH) 2010-01-21 WO disclosed
US-20100016312-A1 Substituted indolyl and indazolyl derivatives and uses thereof ROCHE PALO ALTO LLC 2010-01-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100016312-A1 Substituted indolyl and indazolyl derivatives and uses thereof MAOB, MAOA, TPH1 IMPDH2 182/4885IMPDH1 116/4885NPC1 707/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.